slightbourne@noblecapitalmarkets.com, Author at Channelchek

Apple Hits $4 Trillion Milestone as iPhone 17 Sales Power Market Momentum

Posted on October 28, 2025October 28, 2025 by slightbourne@noblecapitalmarkets.com

Apple has once again proven its staying power in the global tech landscape, briefly touching a $4 trillion market capitalization before pulling back slightly. The milestone underscores renewed investor optimism as strong early sales of the new iPhone 17 lineup signal that Apple’s growth engine remains alive and well.

According to data from Counterpoint Research, the iPhone 17 series outperformed its predecessor, the iPhone 16, during its first 10 days of release in both the U.S. and China—two of Apple’s most important markets. Year over year, iPhone sales surged 14%, with the base iPhone 17 and high-end iPhone 17 Pro drawing the most attention from consumers. The newly introduced iPhone Air also saw solid momentum, slightly outselling the discontinued iPhone Plus.

Apple’s stock climbed on the back of these strong figures, propelling its valuation into the $4 trillion club alongside fellow tech giants Nvidia and Microsoft. While Apple has flirted with this threshold before, the combination of resilient hardware demand and ongoing investor confidence helped push it back into record territory.

Still, not all analysts are convinced the sales surge will hold steady. Recent tracking from Jefferies suggests iPhone demand may be cooling slightly week over week, with delivery lead times shortening across major markets. In the U.S. and Europe, the once-long waits for iPhone 17 Pro and Pro Max models have largely disappeared, hinting that initial supply bottlenecks have eased.

Even so, Apple’s iPhone remains its crown jewel. The device generated $201.2 billion in revenue in 2024, more than half of the company’s total $391 billion. Its Services segment—covering everything from Apple TV+ to iCloud—added another $96.2 billion, showcasing the company’s ability to diversify beyond hardware.

Unlike Nvidia and Microsoft, whose valuations have surged on the strength of artificial intelligence development, Apple has taken a more measured approach. The company has yet to unveil its long-awaited AI-powered version of Siri, even as competitors like Google and Samsung continue to push forward with AI-enhanced products such as Gemini and Galaxy AI.

Despite that, Apple’s ecosystem remains unmatched. With over one billion active iPhones worldwide, along with a growing base of Apple Watch, AirPods, and service subscribers, the company benefits from an unparalleled level of customer loyalty. Each product launch not only drives revenue but reinforces a network of users deeply embedded in Apple’s ecosystem.

For investors, the story is clear: Apple may not be leading the AI revolution—yet—but its scale, cash flow, and brand strength continue to make it one of the most dependable growth stories in global markets. The $4 trillion mark is less about a temporary milestone and more about a company that continues to define what long-term market dominance looks like.

The Beachbody Company (BODI) – Strong Brands To Flex Toward Growth

Posted on October 28, 2025October 28, 2025 by slightbourne@noblecapitalmarkets.com

Tuesday, October 28, 2025

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating with an Outperform rating. After years of revenue declines, we believe that the company is on the cusp of a swing toward revenue growth, offering a breakout opportunity for a stock that has been range-bound. We are initiating coverage with an Outperform rating and a $12 price target.

Well-recognized brands with growth potential. The company has established brands in workout videos, such as Insanity and P90x, and nutritional supplements, including Shakeology, Beachbar, and Beachbody Performance. Such strong brands are expected to support the company’s revenue growth initiatives as it expands distribution of its products into mass merchants.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Great Lakes Dredge & Dock (GLDD) – Some Debt Restructuring

Posted on October 28, 2025October 28, 2025 by slightbourne@noblecapitalmarkets.com

Tuesday, October 28, 2025

Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Debt Restructuring. Yesterday, Great Lakes announced it completed an amendment to its existing Revolving Credit Facility, upsizing the facility by $100 million to $430 million and extending its maturity to October 2030 from June of 2029. We believe the expansion of Great Lakes’ revolving credit facility highlights the strength of the Company’s business and its credit profile.

Second Lien Payoff. Significantly, as part of this transaction, the Company utilized the increased revolver capacity to fully repay the $100 million second lien notes issued in 2024. This will save the Company some $6 million per year in interest expense. Great Lakes’ balance sheet remain solid, with no debt maturities until 2029 and a weighted average interest rate now under 6%.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Fed Poised to Cut Interest Rates Again Despite Data Blackout Amid Government Shutdown

Posted on October 28, 2025October 28, 2025 by slightbourne@noblecapitalmarkets.com

The Federal Reserve is expected to lower interest rates again this week, even as policymakers navigate an unusually uncertain environment caused by the ongoing government shutdown. With most official economic data unavailable since early October, central bank officials are relying on private-sector reports and anecdotal evidence to guide their decision-making.

This marks the second rate cut of 2025, as the Fed continues to balance the dual challenges of cooling inflation and a weakening job market. The shutdown, which began on October 1, has halted the release of key reports, including the monthly jobs data that typically plays a pivotal role in shaping monetary policy. In the absence of those figures, alternative data sources from payroll processors and research firms suggest that hiring has slowed sharply, pointing to potential cracks in the labor market.

Private-sector reports indicate that U.S. employers reduced jobs in September, marking a significant shift from the steady gains earlier in the year. Sectors like healthcare continue to add positions, but most other areas — including manufacturing, construction, and retail — are showing signs of contraction. Economists believe this slowdown reflects weaker demand rather than a shortage of available workers, signaling that the broader economy may be cooling more rapidly than anticipated.

Adding to the complexity, inflation data remains mixed. The Consumer Price Index showed a slight decline in September, with core inflation rising 3% year over year, down from 3.1% the month prior. While the moderation in prices provides some relief, inflation still sits above the Fed’s 2% target. Economists warn that new tariffs and rising consumer costs could keep price pressures elevated in the months ahead, making it harder for policymakers to strike the right balance.

The Fed’s dilemma is compounded by growing signs of financial strain in certain lending markets. Losses in subprime auto loans and stress in commercial lending have raised concerns about the overall health of the financial system. While analysts don’t view these issues as systemic, they consider them early indicators that consumers and smaller banks are under pressure as growth slows.

Despite these warning signs, most analysts expect the Federal Open Market Committee (FOMC) to approve a 0.25% rate cut this week, bringing borrowing costs further down as part of a broader effort to support the labor market. Markets have already priced in another possible cut before year’s end, though the timing and extent of future moves will likely depend on when official government data becomes available again.

Fed Chair Jerome Powell has acknowledged that the lack of reliable data leaves policymakers in a difficult position, forcing them to rely on partial information and economic models to assess risks. With inflation easing slightly but employment softening, the central bank appears committed to erring on the side of supporting growth — even if that means acting with limited visibility.

The path ahead remains uncertain. If inflation stabilizes and job losses accelerate, the Fed may continue cutting rates into early 2026. But if inflation proves more persistent than expected, the central bank could be forced to pause its easing cycle sooner than markets anticipate. Either way, the current data blackout underscores how fragile the economic landscape remains — and how challenging it is for the Fed to steer policy when flying blind.

Novartis’ $12 Billion Avidity Acquisition Strengthens Its Rare Disease Pipeline Amid Pharma Tariff Uncertainty

Posted on October 27, 2025October 27, 2025 by slightbourne@noblecapitalmarkets.com

Swiss pharmaceutical giant Novartis AG announced plans to acquire Avidity Biosciences for approximately $12 billion in cash, a move aimed at deepening its focus on rare and neuromuscular diseases while navigating an increasingly complex U.S. trade and regulatory landscape.

Under the terms of the agreement, Avidity shareholders will receive $72 per share, representing a 46% premium to the company’s most recent closing price. The acquisition, expected to close later this year pending regulatory approval, underscores Novartis’ aggressive strategy to expand its biotech capabilities and offset upcoming patent expirations on several of its blockbuster therapies.

The deal also includes the formation of a new spin-off company, Spinco, which will house Avidity’s early-stage precision cardiology programs. Spinco is expected to operate as an independent, publicly traded firm, led by Avidity’s current Chief Program Officer, Kathleen Gallagher.

Headquartered in San Diego, Avidity Biosciences has gained attention for pioneering a new class of RNA-based therapeutics that directly target muscle tissue. Its lead candidate, Del-zota, is being developed to treat a rare subtype of Duchenne muscular dystrophy (DMD), a debilitating genetic disorder that leads to progressive muscle weakness. Avidity is also advancing two other promising treatments for serious neuromuscular diseases, all of which leverage its proprietary antibody oligonucleotide conjugate (AOC) platform.

For Novartis, this acquisition offers a timely expansion into rare disease treatments — a sector experiencing growing investor interest due to high unmet medical needs and favorable regulatory incentives. The move is consistent with Novartis’ 2024 acquisition of Kate Therapeutics, another biotech developing gene therapies for muscle diseases, as well as its 2025 deals with Anthos Therapeutics and Regulus Therapeutics, collectively strengthening its position in genetic and cardiovascular medicine.

The rare disease market has become an increasingly competitive frontier for pharmaceutical innovation. Analysts note that Novartis’ acquisition spree is partly driven by its looming patent cliff, as flagship drugs such as Entresto, Xolair, and Cosentyx approach the end of their exclusivity periods. By acquiring companies like Avidity, Novartis not only diversifies its revenue base but also positions itself at the forefront of next-generation therapeutics that could define the next decade of biotech innovation.

The acquisition also carries strategic geopolitical undertones. With the Trump administration imposing 39% tariffs on Switzerland earlier this year, Swiss-based pharmaceutical companies face heightened uncertainty over U.S. trade policy. Expanding operations through American biotech acquisitions helps Novartis maintain a strong U.S. presence and mitigate risks tied to international tariffs.

For small-cap investors, the transaction reinforces an ongoing trend in the life sciences sector: large-cap pharma companies are increasingly looking to buy innovation rather than build it in-house. Early-stage biotech firms with validated technologies, particularly in RNA, gene therapy, and rare disease research, continue to attract premium valuations in acquisition deals.

Ultimately, Novartis’ acquisition of Avidity Biosciences is more than just a growth strategy — it’s a signal of where the pharmaceutical industry is heading. With advances in RNA therapeutics and genetic medicine accelerating, investors can expect more high-value takeovers in the months ahead as established players race to secure the next generation of life-changing treatments.

MariMed Inc (MRMD) – A Move Into New York

Posted on October 24, 2025October 24, 2025 by slightbourne@noblecapitalmarkets.com

Friday, October 24, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New York. Continuing its market expansion, MariMed announced a licensing agreement with Farm 2 Hand, LLC, a New York State cannabis license holder, that will introduce the Company’s top-selling portfolio of products throughout New York State. Terms of the agreement were not disclosed. This expansion follows on the heels of the earlier Pennsylvania and Maine expansions, significantly increasing MariMed’s total addressable market, in our view.

Details. Farm 2 Hand intends to manufacture and distribute a variety of MariMed’s edible products as permitted under New York regulations. Those are initially expected to include Betty’s Eddies fruit chews, Bubby’s Baked goods, and InHouse gummies. The products will be produced in a new kitchen that MariMed will design and equip for Farm 2 Hand at Farm 2 Hand’s Bronx production facility.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Cooling Inflation Keeps Fed on Track for Rate Cut

Posted on October 24, 2025October 24, 2025 by slightbourne@noblecapitalmarkets.com

Inflation eased slightly in September, coming in below economists’ expectations and offering fresh signs that price pressures may be gradually cooling. The latest Consumer Price Index (CPI) report showed prices rising 3% year-over-year, just below the 3.1% forecast, and up 0.3% from August. While inflation remains above the Federal Reserve’s 2% target, investors took the softer reading as confirmation that the Fed is likely to move forward with a quarter-point rate cut at its upcoming meeting.

For small-cap investors, this development could be particularly meaningful. Lower interest rates often translate to cheaper borrowing costs, which can provide a boost to smaller, growth-oriented companies that rely more heavily on credit to fund operations and expansion. In contrast to large-cap corporations with stronger balance sheets, small caps tend to feel monetary shifts more directly — both on the upside and downside.

The report also showed encouraging moderation in key components. Core inflation, which excludes volatile food and energy prices, rose 3% year-over-year, slightly cooler than August’s 3.1%. Meanwhile, shelter costs — one of the stickiest contributors to inflation — increased only 0.2% month-over-month, the smallest gain in over two years. Housing and rent data are often lagging indicators, so any sustained cooling there could accelerate broader disinflation trends heading into the new year.

Still, the data wasn’t uniformly positive. Gasoline prices spiked 4.1% in September, driven by higher crude costs and seasonal demand, while apparel and household furnishings also saw noticeable increases. Yet overall, the direction of inflation remains encouraging for equity markets, particularly for rate-sensitive sectors such as small caps, regional banks, and industrials.

Another notable element of this report is the timing. Released amid a prolonged government shutdown, this CPI print is expected to be one of the last reliable economic data points for several months. Economists warn that future readings may rely more heavily on estimates, increasing uncertainty. That backdrop could heighten market volatility — but for investors with a long-term focus, it may also create tactical opportunities in undervalued areas of the market.

Historically, periods of easing inflation paired with falling interest rates have favored small-cap performance relative to large-cap benchmarks. The Russell 2000, for example, has outperformed the S&P 500 during early-stage easing cycles in more than 70% of past Fed transitions. With inflation holding near 3% and rate cuts on the horizon, investors may soon see renewed rotation into smaller, domestically focused companies — especially those positioned to benefit from lower financing costs and rising consumer spending.

While it’s still too early to declare victory over inflation, September’s CPI data supports the narrative of a “soft landing” — an environment where growth slows without tipping into recession. If that holds, small caps could emerge as one of the biggest beneficiaries in the coming months, offering renewed potential for outsized returns as markets adjust to a lower-rate landscape.

Lilly’s Adverum Acquisition Signals Growing Appetite for Gene Therapy Investments

Posted on October 24, 2025October 24, 2025 by slightbourne@noblecapitalmarkets.com

Eli Lilly and Company’s agreement to acquire Adverum Biotechnologies marks another major move in the race to dominate the emerging field of genetic medicine. The deal, announced Friday, highlights the pharmaceutical giant’s commitment to expanding its gene therapy portfolio and targeting treatments that address chronic, age-related diseases — a market expected to grow rapidly over the next decade.

Under the terms of the agreement, Lilly will acquire all outstanding shares of Adverum for $3.56 per share in cash, plus a contingent value right (CVR) worth up to an additional $8.91 per share, depending on key regulatory and sales milestones. This brings the potential total value of the transaction to $12.47 per share. The deal is expected to close by the fourth quarter of 2025, pending shareholder and regulatory approval.

Adverum’s leading asset, Ixo-vec, is a one-time intravitreal gene therapy in Phase 3 development for wet age-related macular degeneration (wAMD) — a progressive retinal condition that affects millions of older adults worldwide. The therapy aims to reduce the need for repeated eye injections by delivering long-term aflibercept production directly within the eye. If successful, Ixo-vec could reshape the standard of care for patients who currently rely on frequent treatments to preserve vision.

The acquisition aligns with Lilly’s broader strategy of integrating genetic medicine technologies into its drug discovery pipeline. The company has already made significant investments in obesity, diabetes, and Alzheimer’s research, and sees gene therapy as a natural extension of that work. By adding Adverum’s proprietary intravitreal delivery platform and its promising ocular gene therapy programs, Lilly gains both innovation and market access in a field expected to see accelerating demand.

From a financial standpoint, the structure of the deal — combining upfront cash with milestone-based CVRs — reflects a balanced approach to managing risk while still rewarding Adverum shareholders if Ixo-vec achieves commercial success. The program’s FDA Fast Track and RMAT designations, as well as PRIME status from the European Medicines Agency, signal strong regulatory support and potential for expedited approval.

The move also underscores a broader trend across the biotech industry: large-cap pharmaceutical companies are increasingly acquiring smaller clinical-stage firms to secure access to cutting-edge gene therapy pipelines. For small-cap investors, this represents an important theme — as emerging biotech companies with late-stage assets become prime takeover targets in the current market cycle.

Gene therapy remains one of the most promising and competitive frontiers in modern medicine. While challenges such as manufacturing scale and long-term efficacy remain, the science continues to mature rapidly. Lilly’s acquisition of Adverum not only validates the commercial potential of ocular gene therapies but also signals continued confidence in the sector’s long-term growth trajectory.

If Ixo-vec succeeds, it could open the door to broader applications of gene therapy across multiple chronic conditions — reinforcing the idea that “one and done” treatments may soon become reality for millions of patients worldwide.

Trump Pardons Binance Founder Changpeng Zhao, Reigniting Debate Over Crypto Regulation

Posted on October 24, 2025October 24, 2025 by slightbourne@noblecapitalmarkets.com

Former President Donald Trump has issued a full pardon for Binance founder Changpeng “CZ” Zhao, closing one of the most closely watched cases in cryptocurrency history and sparking new debate over the direction of U.S. digital asset policy.

Zhao, who had pleaded guilty in 2023 to charges related to money laundering violations during his tenure as CEO of Binance, had been serving a short prison sentence following a landmark $4.3 billion settlement between the crypto exchange and the U.S. Department of Justice. Prosecutors had originally pushed for a multi-year sentence, arguing that Binance’s compliance failures allowed illicit transactions to move through its platform.

The White House described the decision as an effort to correct what it viewed as excessive enforcement against the cryptocurrency sector under the previous administration. Officials suggested that the case against Zhao reflected a broader pattern of hostility toward digital assets that, in their view, discouraged innovation and weakened the United States’ position as a global technology leader.

Zhao’s return to public life is expected to have wide-ranging implications for the crypto industry. Supporters see the pardon as a signal that Washington may adopt a more constructive stance toward blockchain and decentralized finance. Others view it as a politically charged move that raises questions about the growing influence of wealthy crypto figures in U.S. policymaking.

The timing of the pardon has drawn particular attention because of reports linking a Trump-affiliated cryptocurrency venture to trading infrastructure associated with Binance. The project, which reportedly generated billions of dollars in value after the 2024 election, has fueled speculation that Zhao’s reinstatement could strengthen ties between political and corporate crypto interests.

In financial markets, the decision was interpreted as a potential boost for sentiment across the digital asset sector. Traders and fund managers see the move as a possible preview of lighter regulation and renewed growth momentum in an industry that has faced years of uncertainty. Some analysts noted that restoring a high-profile figure like Zhao could accelerate investment in U.S.-based blockchain initiatives, particularly if the administration follows through with policies aimed at promoting innovation and capital formation.

Critics, however, argue that the pardon undermines confidence in fair and consistent regulation. Lawmakers who have long pressed for stricter oversight of cryptocurrency markets warned that leniency toward industry executives could set a troubling precedent, encouraging future violations by major exchanges.

Despite the controversy, the decision underscores the shifting balance of power in Washington as digital assets become a more prominent component of the economy. With Zhao now free to re-enter the industry, Binance and the broader crypto market may find new momentum — though questions about transparency, accountability, and influence are likely to persist.

The pardon not only revives one of crypto’s most influential figures but also signals that the United States may be entering a new era of engagement with digital finance — one defined as much by political calculation as by innovation.

Falling Mortgage Rates Lift U.S. Home Sales — But Prices Remain Stubbornly High

Posted on October 23, 2025October 23, 2025 by slightbourne@noblecapitalmarkets.com

The U.S. housing market gained momentum in September as falling mortgage rates helped drive home sales to their strongest level in seven months. Despite the uptick, prices remain elevated, reflecting the persistent challenges of limited supply and strong demand.

Sales of previously owned homes rose 1.5% from August to a seasonally adjusted annual rate of 4.06 million units, according to the National Association of Realtors. Although slightly below analysts’ expectations, sales were still more than 4% higher than a year earlier, signaling steady improvement in buyer activity.

The increase came as mortgage rates eased during the summer. The average rate on a 30-year fixed loan declined from 6.67% at the start of July to 6.17% by the end of September, making home purchases slightly more affordable for prospective buyers. Improved affordability, combined with rising confidence in the housing market, has encouraged more buyers to return despite lingering concerns about high costs.

Inventory levels also improved modestly, rising 14% from a year ago to 1.55 million homes for sale. However, supply remains below pre-pandemic norms, and at the current sales pace, the market still leans toward sellers. Many homeowners remain financially stable and see little urgency to sell, keeping distressed listings to a minimum.

Prices continued their steady climb in September. The median existing home price reached $415,200, up 2.1% from the previous year and marking the 27th consecutive month of annual gains. Home values are now more than 50% higher than before the pandemic began, underscoring how resilient pricing has remained even in the face of higher borrowing costs over the past two years.

Much of the current growth is being led by the upper end of the market. Sales of homes priced above $1 million jumped roughly 20% from last year, supported by a rise in luxury listings and affluent buyers taking advantage of more favorable borrowing conditions. In contrast, lower-priced homes under $100,000 saw only modest increases, constrained by affordability barriers and limited availability.

First-time buyers are beginning to reappear, accounting for 30% of September transactions compared with 26% a year ago. Lower rates and a modest increase in available homes are helping younger buyers re-engage, although many remain priced out of major metro areas. Roughly 30% of all transactions were completed in cash, highlighting the continued presence of investors and high-net-worth buyers in the market.

Homes are also taking slightly longer to sell, with properties remaining on the market for an average of 33 days compared with 28 a year ago. This may reflect both higher asking prices and a more measured pace among buyers evaluating their options.

Overall, the latest data suggests that easing mortgage rates are breathing some life back into the housing market. However, until supply improves meaningfully and price growth slows, affordability will remain a significant obstacle for many households hoping to buy a home.

The Oncology Institute, Inc. (TOI) – Highlights From Noble’s Virtual Conference

Posted on October 23, 2025October 23, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, October 23, 2025

TOI is an oncology practice management company that provides administrative services to oncology clinics. These clinics provide cancer care to a population of approximately 1.9 million patients. Services include cancer care, pharmacy and dispensary services, clinical trials, and services associated with oncology care. The company employs nearly 120 clinicians and over 700 teammates at over 70 clinic locations.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

TOI Is Addressing The Unsustainable Cost Trend In Oncology. The Oncology Institute manages medical clinics that have improved outcomes and patient satisfaction while reducing the cost of cancer treatment. Dr. Daniel Virnich, CEO, and Rob Carter, CFO, highlighted the benefits of the company’s hybrid model of employed physicians and contracted independent community oncologists. The video of the company’s presentation may be viewed here.

Differentiated Competitive Advantage. TOI distinguishes itself from competitors in the value-based oncology field through its ownership of clinical assets (employed physicians and clinics). This provides greater control over care delivery compared to pure utilization management firms (such as Evolent’s New Century Health) or care navigation models (such as Thyme Care). This control enables higher compliance with value-based prescribing pathways, better integration of ancillary services, and more predictable and significant cost savings for payers.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Superior Group of Companies (SGC) – Looking Beyond The Third Quarter

Posted on October 23, 2025October 23, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, October 23, 2025

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 Preview. We expect that there will be some impact on the third quarter from the “pull forward” in Branded Product revenue into the second quarter as consumers reacted ahead of possible trade policy changes. As such, we are modestly lowering our Q3 revenue and earnings expectations, highlighted in Figure #1 Q3 Revisions.

Largest variance. The largest adjustment to our Q3 revenue estimate is in Branded Products, revised from $89.8 million to $85.0 million. In our view, this segment offers one of the largest upside surprise potential in Q4, which could benefit from an improving macro economy.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Nutriband (NTRB) – Highlights From Noble’s Virtual Conference

Posted on October 23, 2025October 23, 2025 by slightbourne@noblecapitalmarkets.com

Thursday, October 23, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Nutriband Is Developing Transdermal Abuse-Deterrent Technologies. Nutriband has developed abuse-deterrent technology for dermal patch drug delivery. Serguei Melnik, Interim CEO, and Irina Gram, Director, highlighted the company’s platform, known as AVERSA, and its focus on patches containing FDA-approved drugs. The presentation may be viewed here.

Lead Product & Market Opportunity. The lead product, AVERSA Fentanyl, is an abuse-deterrent fentanyl patch. Upon approval, the FDA could mandate such technology for all fentanyl patches, the same way it required opioid pills to have abuse-deterrents. Market analysis by Advanced Health projects annual sales of $200 million for the branded AVERSA Fentanyl. If the abuse-resistant patch were mandated and replaced generic patches, sales could reach $800 million. A patch with improved safety and abuse-deterrence could reverse the decline in fentanyl prescriptions caused by reluctance to prescribe a drug with known abuse potential.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).